MAPT and Alzheimer disease: The study randomised 1736 early AD patients with low/medium or high tau pathology to receive a placebo (876, 80% completing the study) or donanemab (860, 72% completing the study) i.v. every four weeks, at the initial dose of 700 mg for the first three administrations and 1400 mg thereafter for up to 76 weeks.